Cargando…
nab-Paclitaxel as a potential partner with checkpoint inhibitors in solid tumors
Tumors recognized by the host immune system are associated with better survival. However, the immune system is often suppressed in patients with established tumor burden. Stimulating the immune system to detect and kill tumor cells has been a challenge in cancer therapy for some time. Recently, nove...
Autor principal: | |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5189972/ https://www.ncbi.nlm.nih.gov/pubmed/28053544 http://dx.doi.org/10.2147/OTT.S122974 |
_version_ | 1782487325582819328 |
---|---|
author | Soliman, Hatem H |
author_facet | Soliman, Hatem H |
author_sort | Soliman, Hatem H |
collection | PubMed |
description | Tumors recognized by the host immune system are associated with better survival. However, the immune system is often suppressed in patients with established tumor burden. Stimulating the immune system to detect and kill tumor cells has been a challenge in cancer therapy for some time. Recently, novel cancer immunotherapies, such as immune checkpoint inhibitors, monoclonal antibodies, and vaccine therapies, have emerged as promising therapeutic approaches for many solid tumors. However, for some tumors, immunotherapy alone has not provided significant benefits, and some may even be fully resistant to immunotherapy. It has been suggested that the immune system may require “priming” before an immunotherapy can elicit an immune response. Although chemotherapies are believed to be immunosuppressive, when given at the right dose and sequence these agents may provide this “priming” effect for the immune system. In addition to direct cytotoxic killing of tumor cells, standard chemotherapeutic agents can elicit immunogenicity through various mechanisms. This review highlights the general immunomodulatory properties of chemotherapy agents. It also provides a rationale for combined therapy with nab-paclitaxel and immune checkpoint inhibitors. Recent clinical trial data with these combination regimens in solid tumors are presented, along with a summary of ongoing trials. |
format | Online Article Text |
id | pubmed-5189972 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | Dove Medical Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-51899722017-01-04 nab-Paclitaxel as a potential partner with checkpoint inhibitors in solid tumors Soliman, Hatem H Onco Targets Ther Review Tumors recognized by the host immune system are associated with better survival. However, the immune system is often suppressed in patients with established tumor burden. Stimulating the immune system to detect and kill tumor cells has been a challenge in cancer therapy for some time. Recently, novel cancer immunotherapies, such as immune checkpoint inhibitors, monoclonal antibodies, and vaccine therapies, have emerged as promising therapeutic approaches for many solid tumors. However, for some tumors, immunotherapy alone has not provided significant benefits, and some may even be fully resistant to immunotherapy. It has been suggested that the immune system may require “priming” before an immunotherapy can elicit an immune response. Although chemotherapies are believed to be immunosuppressive, when given at the right dose and sequence these agents may provide this “priming” effect for the immune system. In addition to direct cytotoxic killing of tumor cells, standard chemotherapeutic agents can elicit immunogenicity through various mechanisms. This review highlights the general immunomodulatory properties of chemotherapy agents. It also provides a rationale for combined therapy with nab-paclitaxel and immune checkpoint inhibitors. Recent clinical trial data with these combination regimens in solid tumors are presented, along with a summary of ongoing trials. Dove Medical Press 2016-12-21 /pmc/articles/PMC5189972/ /pubmed/28053544 http://dx.doi.org/10.2147/OTT.S122974 Text en © 2017 Soliman. This work is published and licensed by Dove Medical Press Limited The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. |
spellingShingle | Review Soliman, Hatem H nab-Paclitaxel as a potential partner with checkpoint inhibitors in solid tumors |
title | nab-Paclitaxel as a potential partner with checkpoint inhibitors in solid tumors |
title_full | nab-Paclitaxel as a potential partner with checkpoint inhibitors in solid tumors |
title_fullStr | nab-Paclitaxel as a potential partner with checkpoint inhibitors in solid tumors |
title_full_unstemmed | nab-Paclitaxel as a potential partner with checkpoint inhibitors in solid tumors |
title_short | nab-Paclitaxel as a potential partner with checkpoint inhibitors in solid tumors |
title_sort | nab-paclitaxel as a potential partner with checkpoint inhibitors in solid tumors |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5189972/ https://www.ncbi.nlm.nih.gov/pubmed/28053544 http://dx.doi.org/10.2147/OTT.S122974 |
work_keys_str_mv | AT solimanhatemh nabpaclitaxelasapotentialpartnerwithcheckpointinhibitorsinsolidtumors |